Cita APA (7a ed.)

Findlay, A., Turner, C., Schilter, H., Deodhar, M., Zhou, W., Perryman, L., . . . Jarolimek, W. (2021). An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies. Wiley.

Cita Chicago Style (17a ed.)

Findlay, Alison, et al. An Activity‐based Bioprobe Differentiates a Novel Small Molecule Inhibitor from a LOXL2 Antibody and Provides Renewed Promise for Anti‐fibrotic Therapeutic Strategies. Wiley, 2021.

Cita MLA (8a ed.)

Findlay, Alison, et al. An Activity‐based Bioprobe Differentiates a Novel Small Molecule Inhibitor from a LOXL2 Antibody and Provides Renewed Promise for Anti‐fibrotic Therapeutic Strategies. Wiley, 2021.